Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.



This is a "connection" page, showing publications co-authored by Daniel LaBarbera and Hector Esquer.

Connection Strength
  1. Esquer H, Zhou Q, Nemkov T, Abraham AD, Rinaldetti S, Chen YC, Zhang X, Orman MV, D'Alessandro A, Ferrer M, Messersmith WA, LaBarbera DV. Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer. Oncogene. 2021 04; 40(16):2884-2897.
    View in: PubMed
    Score: 0.858
  2. Esquer H, Zhou Q, Abraham AD, LaBarbera DV. Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS Discov. 2020 08; 25(7):734-743.
    View in: PubMed
    Score: 0.812
  3. Rinaldetti S, Zhou Q, Abbott JM, de Jong FC, Esquer H, Costello JC, Theodorescu D, LaBarbera DV. High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes. Int J Mol Sci. 2022 Sep 14; 23(18).
    View in: PubMed
    Score: 0.238
  4. Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961.
    View in: PubMed
    Score: 0.229
  5. Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 08; 19(8):1598-1612.
    View in: PubMed
    Score: 0.203
  6. Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. J Med Chem. 2019 11 27; 62(22):10182-10203.
    View in: PubMed
    Score: 0.196
  7. Prutton KM, Marentette JO, Leifheit BA, Esquer H, LaBarbera DV, Anderson CC, Maclean KN, Roede JR. Oxidative stress as a candidate mechanism for accelerated neuroectodermal differentiation due to trisomy 21. Free Radic Biol Med. 2022 06; 186:32-42.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2023 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)